Experimental Evolution of Reduced Susceptibility to Artemether-Lumefantrine in <i>Plasmodium berghei</i> Following Serial Drug Pressure. [PDF]
Njoroge SM +7 more
europepmc +1 more source
A case-control auditory evaluation of patients treated with artemether-lumefantrine.
Artemether-lumefantrine is the first registered, fixed, artemisinin-based combination treatment. Artemisinin derivatives are highly effective antimalarials with a favorable safety profile.
core
Pharmaceutical quality of artemether-lumefantrine in Rwanda's public health supply chain: a cross-sectional post-market surveillance study. [PDF]
Rutayisire R +7 more
europepmc +1 more source
Efficacy of artemether-lumefantrine for uncomplicated plasmodium falciparum malaria treatment in mozambique: a systematic review and meta-analysis. [PDF]
Nhama A +5 more
europepmc +1 more source
Preparation, characterization and pre-clinical evaluation of artemether-lumefantrine-paracetamol (AL-P) loaded nanocarriers in the treatment of malaria. [PDF]
Muchonjo JK +4 more
europepmc +1 more source
Therapeutic efficacy of artemether-lumefantrine and molecular markers of antimalarial drug resistance in Benin, 2022. [PDF]
Cavros I +19 more
europepmc +1 more source
Monitoring the efficacy of artemether-lumefantrine and artesunate-sulfadoxine/pyrimethamine combinations for treating uncomplicated <i>Plasmodium falciparum</i> malaria in Boali, Central African Republic. [PDF]
Diaman-Ronsone A +6 more
europepmc +1 more source
Efficacy of artemether lumefantrine vs chloroquine for the treatment of Plasmodium Vivax infection in Pakistan. [PDF]
Khan S +8 more
europepmc +1 more source
Gaps in knowledge and use of artemether-lumefantrine among university students in Southwestern Nigeria: A cross-sectional study. [PDF]
Orok E, Olumoko O, Ekada I, Oladunni A.
europepmc +1 more source
Efficacy of artemether-lumefantrine combination for the treatment of uncomplicated Plasmodium falciparum malaria after 16 years of its introduction into Ghana's antimalarial medicines policy. [PDF]
Abuaku B +18 more
europepmc +1 more source

